Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
idrocilamide
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Idrocilamide is a small molecule skeletal muscle relaxant and anti-inflammatory drug used primarily as a topical cream to treat lumbago and other types of muscular pain. It is available by prescription or over-the-counter in France and several other countries. Mechanistically, idrocilamide acts on the central nervous system by influencing motor neurons that control muscle activity. At the cellular level, it decreases sarcoplasmic reticulum calcium release within muscle fibers and facilitates voltage-dependent inactivation of the voltage sensor for excitation-contraction coupling externally. Additionally, it is a potent inhibitor of caffeine metabolism[1][4][5][6].
- Brand names
- TalvalSrilaneRelaxnovaBrolitène
- Other names
- N-(2-hydroxyethyl)cinnamamideN-(2-Hydroxyethyl)-3-phenyl-2-propenamideBrolitene
02
Targets
Cyp (Cyclophilin family)
Beyond the preview
Go deeper on idrocilamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on idrocilamide.